Key result
Cardiac biomarkers, primarily NT-proBNP and cardiac troponin I, are reviewed for their utility in diagnosing and managing heart disease in cats.
This review summarizes the clinical utility of cardiac biomarkers like NT-proBNP and cTnI in feline veterinary cardiology.
May inform feline heart disease management; leaves open prospective validation before routine adoption.
Cardiac biomarkers have been used in cats as part of the clinical assessment of heart disease for over a decade. They are widely available to practitioners through commercial reference laboratories. The evidence base for the use of cardiac biomarkers (primarily N-terminal pro-B type natriuretic peptide and cardiac troponin I) in cats is comprehensively reviewed in this article, focusing on each of six specific areas: distinguishing cardiac from non-cardiac causes of respiratory distress; measurement of cardiac biomarkers in urine and pleural fluid; identification of occult cardiomyopathy; effects of systemic disease on circulating concentrations of cardiac biomarkers; point-of-care biomarker testing, and the possible prognostic utility of cardiac biomarker measurement.
No takes yet. Share an insight, caveat, or question.
Borgeat et al. (2015) conducted a review in Heart disease in cats. Cardiac biomarkers (NT-proBNP and cardiac troponin I) was evaluated. Cardiac biomarkers, primarily NT-proBNP and cardiac troponin I, are reviewed for their utility in diagnosing and managing heart disease in cats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: